Participant Flow



Baseline Characteristics

Table 11.2.1 Summary of Participant Demographics (Safety Set)

Parameter	Statistic	Overall (N=24)
Height (m)	n	24
	Mean	1.737
	SD	0.0985
	Min	1.52
	Max	1.92
Weight (kg)	n	24
	Mean	82.28
	SD	11.510
	Min	55.0
	Max	102.2
BMI (kg/m^2)	n	24
	Mean	27.282
	SD	3.1031
	Min	19.71
	Max	31.71
Age at Informed Consent (yrs)	n	24
	Mean	41.1
	SD	8.22
	Min	25
	Max	56
Gender:		
Male	n (%)	16 (66.7)
Female	n (%)	8 (33.3)
Ethnicity:		
Not Hispanic or Latino	n (%)	24 (100)
Hispanic Or Latino	n (%)	0
Race:		
Black Or African American	n (%)	0
American Indian or Alaska Native	n (%)	0
Asian	n (%)	0
Native Hawaiian or Other Pacific Islander	n (%)	0
White	n (%)	24 (100)
Mixed	n (%)	0
Other	n (%)	0

Percentages are based on the total number of subjects in the Safety Set.
BMI = body mass index
Data Source: Table 14.1.2.1

Outcome Measures

Table 11.4.1 Summary of Baseline-Corrected Plasma Nicotine PK Parameters (PK Set)

Product	Summary Statistic	C_{max} (ng/mL)	T_{max} (min)	AUC_{0-240} (min*ng/mL)	AUC_{last} (min*ng/mL)
Product A (N=23)	n	23	23	23	23
	Mean	7.46	N/A	403	363
	SD	5.06	N/A	209	212
	SE	1.05	N/A	43.7	44.2
	Geo. Mean	5.97	N/A	337	288
	Geo. CV%	81.1	N/A	75.5	89.5
	Min	1.49	5.00	67.0	49.0
	Median	6.33	7.00	437	375
	Max	22.8	30.00	755	699
Product B (N=23)	n	23	23	23	23
	Mean	9.01	N/A	507	486
	SD	6.54	N/A	295	307
	SE	1.36	N/A	61.6	64.0
	Geo. Mean	7.08	N/A	381	342
	Geo. CV%	86.4	N/A	115.3	138.0
	Min	1.15	5.00	31.7	21.9
	Median	8.06	7.00	557	557
	Max	30.4	15.00	933	933
Product C (N=23)	n	23	23	23	23
	Mean	15.4	N/A	973	969
	SD	10.8	N/A	285	293
	SE	2.26	N/A	59.5	61.1
	Geo. Mean	12.9	N/A	933	925
	Geo. CV%	63.3	N/A	31.3	33.2
	Min	4.21	5.00	432	432
	Median	11.5	7.00	946	946
	Max	50.3	30.00	1730	1730

Product A: Ploom X and Tobacco Stick – EVO Gold; Product B: Ploom X and Tobacco Stick – EVO Tan; Product C: Combustible cigarettes (own brand).
LLOQ = 0.497 ng/mL (4.973 ng/mL for subject 014, on Day 1, 5 min timepoint). BLQ values imputed as 0.
Baseline defined as pre-IP use. Any negative values occurring as a result of baseline-correction were set to 0 prior to PK parameter derivation.
BLQ = below the limit if quantification, IP = investigational product, LLOQ = lower limit of quantification, min = minute(s), N/A = Not applicable, PK = pharmacokinetic
Data Source: Table 14.4.2.2

Table 11.4.2 Summary of Intent to Use Product Again VAS Score (Safety Set)

Product	Time	n	Mean	SD	Min	Median	Max
Product A (N=24)	15 Min	24	44.7	32.37	0	60.0	94
	8 H	24	47.2	32.84	0	56.5	100
Product B (N=24)	15 Min	24	41.5	26.36	0	38.0	84
	8 H	24	32.7	28.10	0	27.0	86
Product C (N=24)	15 Min	24	91.0	11.20	53	94.5	100
	8 H	24	86.0	20.72	31	92.0	100

Product A: Ploom X and Tobacco Stick – EVO Gold; Product B: Ploom X and Tobacco Stick – EVO Tan; Product C: Combustible cigarettes (own brand).
Response measured on a 100 mm VAS from 0 = "Definitely would not" to 100 = "Definitely would".
VAS = visual analogue scale
Data Source: Table 14.6.1.1

Table 11.4.3 Summary of Urge to Smoke VAS Score (Safety Set)

Product	Time	n	Mean	SD	Min	Median	Max
Product A (N=24)	Pre-IP Use	24	79.3	14.70	34	78.0	100
	15 Min	24	40.5	28.20	4	31.0	98
Product B (N=24)	Pre-IP Use	24	80.5	14.80	51	82.0	100
	15 Min	24	41.5	28.10	0	39.0	97
Product C (N=24)	Pre-IP Use	24	76.3	18.92	19	79.5	100
	15 Min	24	27.0	25.60	2	18.0	92

Product A: Ploom X and Tobacco Stick – EVO Gold; Product B: Ploom X and Tobacco Stick – EVO Tan; Product C: Combustible cigarettes (own brand).
Response measured on a 100 mm VAS from 0 = "Not at all" to 100 = "Extreme".
VAS = visual analogue scale
Data Source: Table 14.6.1.2

Table 11.4.4 Summary of Product Consumption (Safety Set)

Product	Regimen	Number of Sticks/Cigarettes					
		n	Mean	SD	Minimum	Median	Maximum
Product A (N=24)	Multiple Use	24	2.6	1.14	1	2.5	5
Product B (N=24)	Multiple Use	24	2.4	1.18	0	3.0	4
Product C (N=24)	Multiple Use	24	3.4	1.58	1	3.0	7

Product A: Ploom X and Tobacco Stick – EVO Gold; Product B: Ploom X and Tobacco Stick – EVO Tan; Product C: Combustible cigarettes (own brand).
Data Source: Table 14.6.2.1

Adverse Events

A total of 5 PEAEs were reported by 4 (16.7%) participants after use of Product A or Product C. All were mild or moderate and with exception of 1 event of dizziness following use of Product C (reasonable possible relationship to IP), were considered of no reasonable possible relationship to IP. There were no PEAEs following Product B. No SAEs, PEAEs leading to withdrawal of IP or PEAEs leading to death were reported.

Table 12.2.1 Overall Summary of PEAEs (Safety Set)

	Product A (N=24)	Product B (N=24)	Product C (N=24)	Overall (N=24)
Number of PEAEs	2	0	3	5
Number of Study IP-Related PEAEs	0	0	1	1
Number (%) of participants reporting at least one:				
PEAE	2 (8.3)	0	3 (12.5)	4 (16.7)
Serious PEAE	0	0	0	0
PEAE Leading to Withdrawal	0	0	0	0
PEAE Leading to Death	0	0	0	0
Number (%) of participants with PEAE by severity:				
Mild	0	0	2 (8.3)	2 (8.3)
Moderate	2 (8.3)	0	1 (4.2)	2 (8.3)
Severe	0	0	0	0
Number (%) of participants with PEAE by relationship to IP:				
Reasonable Possibility	0	0	1 (4.2)	1 (4.2)
No Reasonable Possibility	2 (8.3)	0	2 (8.3)	3 (12.5)

Product A: Ploom X and Tobacco Stick – EVO Gold; Product B: Ploom X and Tobacco Stick – EVO Tan; Product C: Combustible cigarettes (own brand).
A participant with multiple adverse events is counted only once at the maximum level of severity or the strongest relationship to IP within a product.
IP-related PEAEs are adverse events where causality is reported as reasonable possibility.
Percentages calculated from the number of participants in the Safety Set within a product.
IP = investigational product, PEAEs = product-emergent adverse event
Data Source: Table 14.3.1.1

Table 12.2.2 PEAEs in each Group by System Organ Class and Preferred Term (Safety Set)

SYSTEM ORGAN CLASS Preferred Term	Number of Events / Number (%) of Participants			
	Product A (N=24)	**Product B (N=24)**	**Product C (N=24)**	**Overall (N=24)**
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS:				
Back pain	1 / 1 (4.2)	0	1 / 1 (4.2)	2 / 1 (4.2)
Pain in extremity	0	0	1 / 1 (4.2)	1 / 1 (4.2)
NERVOUS SYSTEM DISORDERS:				
Dizziness	0	0	1 / 1 (4.2)*	1 / 1 (4.2)
Headache	1 / 1 (4.2)	0	0	1 / 1 (4.2)

* One (1) event of dizziness in 1 participant was considered IP-related (reasonable possibility of relationship to IP).
Product A: Ploom X and Tobacco Stick – EVO Gold; Product B: Ploom X and Tobacco Stick – EVO Tan; Product C: Combustible cigarettes (own brand).
A participant is counted only once per system organ class and preferred term within a product.
Percentages calculated from the number of participants in the Safety Set within a product.
MedDRA version 27.0.
IP = investigational product, MedDRA = Medical Dictionary for Regulatory Activities
Data Source: Table 14.3.1.2, Table 14.3.1.3, Listing 16.2.7.2